Silver Book Fact

Savings associated with t-PA treatment for ischemic stroke patients

A $600 net savings is associated with each ischemic stroke patient treated with t-PA. In 2005, only 2% of all ischemic stroke patients received t-PA. If that percentage was increased to 4% the realized cost savings would be approximately $15 million. If increased to 20%, the savings would be around $74 million.

Demaerschalk, BM and TR Yip. Economic Benefit of Increasing Utilization of Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke in the United States. Stroke. 2005; 36(11): 2500-3. http://stroke.ahajournals.org/cgi/content/full/36/11/2500

Reference

Title
Economic Benefit of Increasing Utilization of Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke in the United States
Publication
Stroke
Publication Date
2005
Authors
Demaerschalk, BM and TR Yip
Volume & Issue
Volume 36, Issue 11
Pages
2500-3
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • In the absence of antihypertensive drug therapy, there would have been an estimated 572,000 more hospital discharges for stroke in 2002, and 261,000 more discharges for myocardial infarction. The…  
  • Antihypertensive therapy has been associated in clinical trials with a 1/3 reduction in stroke incidence, a 1/4 reduction in myocardical infarctions and a more than 1/2 reduction in heart failure.  
  • Since 1950, reduction in heart disease mortality has added more than 3 1/2 years to the expected lifetimes of both men and women.  
  • Major cardiovascular event rates could be reduced by 80% simply by acting on known risk factors with therapies already shown to be effective.  
  • The age-adjusted stroke mortality rate has decreased 70% since 1950, and 64% since 1972.